The Technical Analyst
Cocrystal Pharma Inc [COCP]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Cocrystal Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.66% $0.395
Last updated: 3 jul 2022 - 20:16
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 38.50 mill |
| EPS: | -0.165 |
| P/E: | 0.000 |
| Earnings Date: | Aug 15, 2022 |
| SharesOutstanding: | 97.47 mill |
| Avg Daily Volume: | 0.210 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| True Range Average |
|---|
|
+/- $0.0340 ( +/- 8.61%) Range: 0.361 - 0.429 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-08-20 | Pfenniger Richard C Jr | Buy | 40 000 | Common Stock |
| 2021-07-16 | Martin James Joseph | Buy | 250 000 | Stock Options (Right to Buy) |
| 2021-07-16 | Frost Phillip Md Et Al | Buy | 65 000 | Stock Options (Right to Buy) |
| 2021-07-16 | Pfenniger Richard C Jr | Buy | 50 000 | Stock Options (Right to Buy) |
| 2021-07-16 | Kornberg Roger D. | Buy | 65 000 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 18.76 |
| Last 92 transactions |
| Buy: 453 925 162 | Sell: 59 808 344 |
Forecast:
16:00 - $0.400
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.400
Forecast 2: 16:00 - $0.400
Forecast 3: 16:00 - $0.400
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.395 (-3.66% ) |
| Volume | 0.0477 mill |
| Avg. Vol. | 0.210 mill |
| % of Avg. Vol | 22.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
COCP
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 10 full-time employees. The firm focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The firm focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The firm uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The firm is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.
Latest Press Releases
2022-05-11 08:00:00 - Press Release
Cocrystal Pharma Reports First Quarter 2022 Financial Results And Provides Updates On Its Antiviral Development Programs And Milestones
Bothell, wash., may 11, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) reports financial results for the three months ended march 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
2022-04-12 08:00:00 - Press Release
Cocrystal Pharma Reports Favorable Preliminary Data From Phase 1 Initial Cohorts With Cc-42344, A Novel, Broad-spectrum Influenza A Antiviral
Cc-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile
2022-03-23 16:05:00 - Press Release
Cocrystal Pharma Reports 2021 Financial Results And Provides Updates On Development Programs And Milestones
Bothell, wash., march 23, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) reports financial results for the 12 months ended december 31, 2021, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
2022-03-22 08:00:00 - Press Release
Cocrystal Pharma To Participate In The Maxim Group 2022 Virtual Growth Conference
Bothell, wash., march 22, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) announces that management will participate in the 2022 virtual growth conference, presented by maxim group and hosted by m-vest, being held march 28-30, 2022. those interested in attending the virtual conference can register here .
2022-01-27 08:00:00 - Press Release
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates For Its Covid-19 Oral Drug Program
Novel broad-spectrum oral lead candidates cdi-988 and cdi- 873 , discovered using cocrystal's antiviral drug discovery platform , demonstrate superior in vitro potency against sars-cov-2 and activity against all variants of concern including omicron
Latest News
2022-05-18 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.
2022-04-19 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSINW) Conference being held April 20-21, 2022 at the Washington State Convention Center in Seattle. Dr. Lee's presentation is scheduled during the Neuroscience & Pharmaceuticals segment on Wednesday, April 20 at 3:25 p.m. Pacific time.
2022-04-12 11:08:04 - Benzinga
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-.
2022-01-27 12:22:31 - Benzinga
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.
2021-12-08 13:20:18 - PennyStocks
4 Biotech Penny Stocks to Watch With New Catalysts
These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-15 13:55:13 - Zacks Investment Research
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-08 16:06:16 - Zacks Investment Research
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-11-01 19:24:29 - Benzinga
Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
2021-10-14 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021
BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.
2021-10-06 08:49:00 - GlobeNewsWire
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces receipt of clearance from an Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 trial with its orally administered PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.